Dominic Risso-Gill's questions to Altimmune Inc (ALT) leadership • Q2 2025
Question
Dominic Risso-Gill of Piper Sandler Companies questioned if any alcohol consumption data was collected in the IMPACT NASH study that could help de-risk the RECLAIM and RESTORE trials for AUD and ALD. He also asked about the readout timing and the criteria for advancing these programs to Phase 3.
Answer
Chief Medical Officer Dr. M. Scott Harris stated that the IMPACT data is still being analyzed for alcohol measures and updates will be provided later. He expressed confidence in the AUD/ALD programs based on strong preclinical data and the known effects of GLP-1 agents, adding that Phase 3 plans will be determined after meeting with the FDA post-Phase 2.